FDA Program Cuts Loom If ‘Cures’ Bill Isn’t Fully Funded, Ostroff Warns
FDA’s acting commissioner says agency may have to ‘stop doing something else’ in order to cover the new responsibilities envisioned in the Cures legislation.
FDA’s acting commissioner says agency may have to ‘stop doing something else’ in order to cover the new responsibilities envisioned in the Cures legislation.